This technology is a scavenging nanoparticle platform for targeted treatment of metastatic tumors and associated pain.
Chemotherapies often lead to drug resistance and are associated with various systemic side effects. Additionally, cancer patients often experience severe inflammation and pain, highlighting the need for targeted therapeutics that mitigate nociception while effectively eliminating malignant cells.
This technology is a multifunctional scavenging nanoparticle (NP) for targeted treatment of metastatic tumors and inflammation. This technology can modulate pro-inflammatory and pro-migratory toll-like receptor (TLR) activation, demonstrating a longer circulation time and enhanced tumor targeting efficiency compared to free drugs. The NPs can incorporate chemotherapeutics and other agents for targeted cancer treatment. Additionally, this technology can be modified to package pain receptor-specific antagonists for intervention against cancer-related pain.
This technology has been demonstrated in mouse models to mediate pro-migratory and pro-inflammatory TLR activation with longer circulation time than free drugs.
Patent Pending(US/2025/0090489)
IR CU21031
Licensing Contact: Joan Martinez